Cargando…

Epidermal growth factor receptor signaling and the progression of diabetic nephropathy

Detalles Bibliográficos
Autor principal:	Koya, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578489/ https://www.ncbi.nlm.nih.gov/pubmed/26421143 http://dx.doi.org/10.1111/jdi.12317

Ejemplares similares

Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?
por: Musgrove, Elizabeth A
Publicado: (2004)

Radiosensitization of head and neck cancer by targeting the epidermal growth factor receptor
por: Goel, Arun Kumar, et al.
Publicado: (2009)

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization
por: Gee, Julia MW, et al.
Publicado: (2003)

Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells
por: van Rossum, Agnes GSH, et al.
Publicado: (2005)

Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy
por: Kume, Shinji, et al.
Publicado: (2008)

Epidermal growth factor receptor (EGFR) biology and Wnt developmental signaling highlight research endeavors of SCBA award winners
por: Jeang, Kuan-Teh
Publicado: (2012)

Urinary adiponectin and progression of diabetic nephropathy in type 1 diabetes
por: Ha, Kyoung Hwa, et al.
Publicado: (2015)

Role of Nutrient-Sensing Signals in the Pathogenesis of Diabetic Nephropathy
por: Kume, Shinji, et al.
Publicado: (2014)

Impact of empagliflozin on diabetic kidney disease
por: Koya, Daisuke
Publicado: (2017)

Epidermal Growth Factor Receptor Inhibition Slows Progression of Diabetic Nephropathy in Association With a Decrease in Endoplasmic Reticulum Stress and an Increase in Autophagy
por: Zhang, Ming-Zhi, et al.
Publicado: (2014)

Commentary: Guideline for Performing Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Quantitative Image Analysis well
por: Beckwith, Bruce
Publicado: (2019)

Does Losartan Prevent Progression of Early Diabetic Nephropathy in American Indians With Type 2 Diabetes?
por: Nicholas, Susanne B., et al.
Publicado: (2013)

Dual protein kinase C alpha and beta inhibitors and diabetic kidney disease: a revisited therapeutic target for future clinical trials
por: Koya, Daisuke
Publicado: (2013)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Lipid mediators in diabetic nephropathy
por: Srivastava, Swayam Prakash, et al.
Publicado: (2014)

Nutrient Sensing, Autophagy, and Diabetic Nephropathy
por: Kume, Shinji, et al.
Publicado: (2012)

Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy
por: Kume, Shinji, et al.
Publicado: (2015)

Rodent models of diabetic nephropathy: their utility and limitations
por: Kitada, Munehiro, et al.
Publicado: (2016)

Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

The Challenging Search for Diabetic Nephropathy Genes
por: Bowden, Donald W., et al.
Publicado: (2012)

The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Avila, Jorge, et al.
Publicado: (2023)

Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways
por: Carpenter, Graham
Publicado: (1999)

Epigenetic regulation of core genes linking to diabetic nephropathy progression: Lesson from FinnDiane type 1 diabetes study
por: Makino, Hirofumi, et al.
Publicado: (2023)

Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis
por: Kanasaki, Keizo, et al.
Publicado: (2013)

A new analysis approach of epidermal growth factor receptor pathway activation patterns provides insights into cetuximab resistance mechanisms in head and neck cancer
por: von der Heyde, Silvia, et al.
Publicado: (2012)

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
por: Giuliani, Jacopo, et al.
Publicado: (2021)

The Role of Autophagy in the Pathogenesis of Diabetic Nephropathy
por: Yamahara, Kosuke, et al.
Publicado: (2013)

Redox-dependent regulation of epidermal growth factor receptor signaling
por: Heppner, David E., et al.
Publicado: (2015)

Spatial Regulation of Epidermal Growth Factor Receptor Signaling by Endocytosis
por: Ceresa, Brian P.
Publicado: (2012)

Kindlin-1 Regulates Epidermal Growth Factor Receptor Signaling
por: Michael, Magdalene, et al.
Publicado: (2019)

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
por: Wee, Ping, et al.
Publicado: (2017)

Diabetic Nephropathy: Emerging Biomarkers for Risk Assessment
por: Badal, Shawn S., et al.
Publicado: (2015)

Losartan and diabetic nephropathy: commentaries on the RENAAL study
por: Fisman, Enrique Z, et al.
Publicado: (2002)

MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma
por: Yang, Mengkai, et al.
Publicado: (2021)

The Role of the Epidermal Growth Factor Receptor in Diabetic Kidney Disease
por: Harris, Raymond C.
Publicado: (2022)

Nrf2 Activators as Attractive Therapeutics for Diabetic Nephropathy
por: de Haan, Judy B.
Publicado: (2011)

Values and Limitations of Targeting lncRNAs in Diabetic Nephropathy
por: Long, Jianyin, et al.
Publicado: (2018)

Pembrolizumab-Associated Nerve Epidermal Growth Factor-Like 1 Membranous Nephropathy
por: Nimkar, Abhishek, et al.
Publicado: (2022)

Vitamin D in diabetic nephropathy
por: Prabhu, RA, et al.
Publicado: (2018)

The Yin and Yang of vitamin D receptor (VDR) signaling in neoplastic progression: Operational networks and tissue-specific growth control
por: Campbell, F.C., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_qv556dmk5ttmq844rma374mf3j